Research
The technology developed by Polytheragene originates from research carried out to produce synthetic vectors for the transfer of nucleic acids (DNA and RNA) and hydrophobic active ingredients.
Innovation
Polytheragene’s activity lies in the development of polymeric vectors with very low toxicity in vitro and in vivo.
The first family concerns cationic polymers – PTG1 and PTG3 – containing histidine. PTG1 and PTG3 are effective for the transfection of DNA plasmids and mRNA. They are very effective for the transfection of HEK293T and CHO cells for the bioproduction of viruses and proteins.
The second family concerns neutral tri-block copolymers (PTG2) which are very effective for the solubilization and vectorization of hydrophobic active ingredients.
Development
Research and development activities are underway to make them more efficient and more selective. Polymers can be functionalized with fluorescent or spectroscopically active molecules and/or other molecules for targeting.